Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 31,113
- Estimated value
- $928,723
- Report date
- 04 May 2026
- Price
- $29.85
- Ownership
- Direct
Charles J. Homcy - Director at Maze Therapeutics, Inc.
Issuer-level insider activity
- Role
- Director
- Issuer ticker
- MAZE on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Charles J. Homcy since 07 Jun 2025
Reported holdings for Charles J. Homcy in Maze Therapeutics, Inc.
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 7,422
- Estimated value
- $246,558
- Report date
- 19 Nov 2025
- Price
- $33.22
- Ownership
- By Trust
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 18,000
- Estimated value
- Report date
- 22 Sep 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Series D-1 Preferred Stock
- Shares / value
- 7,422
- Estimated value
- Report date
- 26 Nov 2024
- Price
- Ownership
- By Trust
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 03 Feb 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 03 Feb 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Maze Therapeutics, Inc.
- Security class
- 8% Convertible Note due 2026
- Shares / value
- $0
- Estimated value
- Report date
- 26 Nov 2024
- Price
- Ownership
- By Trust
- Underlying class
- Series D-1 Preferred Stock
- Underlying amount
Transaction history for Charles J. Homcy in Maze Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.